Leading Global CRO Expands into Western Europe, Establishes its European Headquarters in Frankfurt, Germany
Biorasi LLC, award-winning global CRO, announced today that it has completed the acquisition of Advanced Biosciences Research (ABR), a leading European CRO with operations in United Kingdom, Germany, Switzerland, and Sweden. ABR is a highly integrated group that has provided Phase II to IV clinical research project management, monitoring, and regulatory outsourcing for its sponsors in the region.
"This move is strategically crucial to addressing the ever-increasing demand for delivering Clinical Research Optimized™ globally," explained Dr. Boris Reznik, Chairman of Biorasi. "Our ProAct+™ platform is the foundation of unparalleled global integration of our project operations. It guides, adapts and improves every clinical trial planning and execution process. Expanding our Western European Operations dramatically increases its optimization capability."
"We have been working with Biorasi for over a year and have been extremely impressed with the superiority of Biorasi's innovative clinical research project delivery model. Its ProAct+™ platform does not have equals in our industry." explained Dr. Tigran Arzumanov, ABR Principle. "We are excited to be a part of Biorasi's team."
Biorasi has been running world-wide clinical trials for over a decade.It has maintained a formidable presence in North and South America, Eastern Europe and Asia. The addition of ABR's regional base to Biorasi unmatched strength in Russia and Ukraine, and a decade-long established presence in Czech Republic, Poland, Serbia, Latvia, and United Kingdom, creates a very strong footprint throughout Europe.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.